

## [Doxorubicin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01DB01](#)

EMLc

Indication

Kaposi sarcoma of unspecified primary site ICD11 code: [2C27.Z](#)

INN

Doxorubicin

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Doxorubicin](#)

DrugBank

[Doxorubicin](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.